2024-03-012025-02-282025-02-28false05241106MOTTS PHARMACY LIMITED2025-11-17falseiso4217:GBPxbrli:pure052411062024-02-29052411062025-02-28052411062024-03-012025-02-28052411062023-02-28052411062024-02-29052411062023-03-012024-02-2905241106bus:SmallEntities2024-03-012025-02-2805241106bus:AuditExempt-NoAccountantsReport2024-03-012025-02-2805241106bus:FullAccounts2024-03-012025-02-2805241106bus:PrivateLimitedCompanyLtd2024-03-012025-02-2805241106core:WithinOneYear2025-02-2805241106core:AfterOneYear2025-02-2805241106core:WithinOneYear2024-02-2905241106core:AfterOneYear2024-02-2905241106core:ShareCapital2025-02-2805241106core:SharePremium2025-02-2805241106core:RevaluationReserve2025-02-2805241106core:OtherReservesSubtotal2025-02-2805241106core:RetainedEarningsAccumulatedLosses2025-02-2805241106core:ShareCapital2024-02-2905241106core:SharePremium2024-02-2905241106core:RevaluationReserve2024-02-2905241106core:OtherReservesSubtotal2024-02-2905241106core:RetainedEarningsAccumulatedLosses2024-02-2905241106core:LandBuildings2025-02-2805241106core:PlantMachinery2025-02-2805241106core:Vehicles2025-02-2805241106core:FurnitureFittings2025-02-2805241106core:OfficeEquipment2025-02-2805241106core:NetGoodwill2025-02-2805241106core:IntangibleAssetsOtherThanGoodwill2025-02-2805241106core:ListedExchangeTraded2025-02-2805241106core:UnlistedNon-exchangeTraded2025-02-2805241106core:LandBuildings2024-02-2905241106core:PlantMachinery2024-02-2905241106core:Vehicles2024-02-2905241106core:FurnitureFittings2024-02-2905241106core:OfficeEquipment2024-02-2905241106core:NetGoodwill2024-02-2905241106core:IntangibleAssetsOtherThanGoodwill2024-02-2905241106core:ListedExchangeTraded2024-02-2905241106core:UnlistedNon-exchangeTraded2024-02-2905241106core:LandBuildings2024-03-012025-02-2805241106core:PlantMachinery2024-03-012025-02-2805241106core:Vehicles2024-03-012025-02-2805241106core:FurnitureFittings2024-03-012025-02-2805241106core:OfficeEquipment2024-03-012025-02-2805241106core:NetGoodwill2024-03-012025-02-2805241106core:IntangibleAssetsOtherThanGoodwill2024-03-012025-02-2805241106core:ListedExchangeTraded2024-03-012025-02-2805241106core:UnlistedNon-exchangeTraded2024-03-012025-02-2805241106core:MoreThanFiveYears2024-03-012025-02-2805241106core:Non-currentFinancialInstruments2025-02-2805241106core:Non-currentFinancialInstruments2024-02-2905241106dpl:CostSales2024-03-012025-02-2805241106dpl:DistributionCosts2024-03-012025-02-2805241106core:LandBuildings2024-03-012025-02-2805241106core:PlantMachinery2024-03-012025-02-2805241106core:Vehicles2024-03-012025-02-2805241106core:FurnitureFittings2024-03-012025-02-2805241106core:OfficeEquipment2024-03-012025-02-2805241106dpl:AdministrativeExpenses2024-03-012025-02-2805241106core:NetGoodwill2024-03-012025-02-2805241106core:IntangibleAssetsOtherThanGoodwill2024-03-012025-02-2805241106dpl:GroupUndertakings2024-03-012025-02-2805241106dpl:ParticipatingInterests2024-03-012025-02-2805241106dpl:GroupUndertakingscore:ListedExchangeTraded2024-03-012025-02-2805241106core:ListedExchangeTraded2024-03-012025-02-2805241106dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-03-012025-02-2805241106core:UnlistedNon-exchangeTraded2024-03-012025-02-2805241106dpl:CostSales2023-03-012024-02-2905241106dpl:DistributionCosts2023-03-012024-02-2905241106core:LandBuildings2023-03-012024-02-2905241106core:PlantMachinery2023-03-012024-02-2905241106core:Vehicles2023-03-012024-02-2905241106core:FurnitureFittings2023-03-012024-02-2905241106core:OfficeEquipment2023-03-012024-02-2905241106dpl:AdministrativeExpenses2023-03-012024-02-2905241106core:NetGoodwill2023-03-012024-02-2905241106core:IntangibleAssetsOtherThanGoodwill2023-03-012024-02-2905241106dpl:GroupUndertakings2023-03-012024-02-2905241106dpl:ParticipatingInterests2023-03-012024-02-2905241106dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-012024-02-2905241106core:ListedExchangeTraded2023-03-012024-02-2905241106dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-012024-02-2905241106core:UnlistedNon-exchangeTraded2023-03-012024-02-2905241106core:NetGoodwill2025-02-2805241106core:IntangibleAssetsOtherThanGoodwill2025-02-2805241106core:LandBuildings2025-02-2805241106core:PlantMachinery2025-02-2805241106core:Vehicles2025-02-2805241106core:FurnitureFittings2025-02-2805241106core:OfficeEquipment2025-02-2805241106core:AfterOneYear2025-02-2805241106core:WithinOneYear2025-02-2805241106core:ListedExchangeTraded2025-02-2805241106core:UnlistedNon-exchangeTraded2025-02-2805241106core:ShareCapital2025-02-2805241106core:SharePremium2025-02-2805241106core:RevaluationReserve2025-02-2805241106core:OtherReservesSubtotal2025-02-2805241106core:RetainedEarningsAccumulatedLosses2025-02-2805241106core:NetGoodwill2024-02-2905241106core:IntangibleAssetsOtherThanGoodwill2024-02-2905241106core:LandBuildings2024-02-2905241106core:PlantMachinery2024-02-2905241106core:Vehicles2024-02-2905241106core:FurnitureFittings2024-02-2905241106core:OfficeEquipment2024-02-2905241106core:AfterOneYear2024-02-2905241106core:WithinOneYear2024-02-2905241106core:ListedExchangeTraded2024-02-2905241106core:UnlistedNon-exchangeTraded2024-02-2905241106core:ShareCapital2024-02-2905241106core:SharePremium2024-02-2905241106core:RevaluationReserve2024-02-2905241106core:OtherReservesSubtotal2024-02-2905241106core:RetainedEarningsAccumulatedLosses2024-02-2905241106core:NetGoodwill2023-02-2805241106core:IntangibleAssetsOtherThanGoodwill2023-02-2805241106core:LandBuildings2023-02-2805241106core:PlantMachinery2023-02-2805241106core:Vehicles2023-02-2805241106core:FurnitureFittings2023-02-2805241106core:OfficeEquipment2023-02-2805241106core:AfterOneYear2023-02-2805241106core:WithinOneYear2023-02-2805241106core:ListedExchangeTraded2023-02-2805241106core:UnlistedNon-exchangeTraded2023-02-2805241106core:ShareCapital2023-02-2805241106core:SharePremium2023-02-2805241106core:RevaluationReserve2023-02-2805241106core:OtherReservesSubtotal2023-02-2805241106core:RetainedEarningsAccumulatedLosses2023-02-2805241106core:AfterOneYear2024-03-012025-02-2805241106core:WithinOneYear2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:CostValuation2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2805241106core:Non-currentFinancialInstrumentscore:CostValuation2025-02-2805241106core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-2805241106core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-2805241106core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-2805241106core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-2805241106core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-2805241106core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-2805241106core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-2805241106core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-2805241106core:Non-currentFinancialInstrumentscore:CostValuation2024-02-2905241106core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-2905241106core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-2905241106core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-2905241106core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-2905241106core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-2905241106core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-2905241106core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-2905241106core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-2905241106bus:Director12024-03-012025-02-2805241106bus:Director22024-03-012025-02-2805241106core:FurnitureFittingsToolsEquipment2024-02-2905241106core:FurnitureFittingsToolsEquipment2024-03-012025-02-2805241106core:FurnitureFittingsToolsEquipment2025-02-28

MOTTS PHARMACY LIMITED

Registered Number
05241106
(England and Wales)

Unaudited Financial Statements for the Year ended
28 February 2025

MOTTS PHARMACY LIMITED
Company Information
for the year from 1 March 2024 to 28 February 2025

Directors

KULAR, Gurpreet
KULAR, Rupan

Registered Address

Market Place
Reepham
Norwich
NR10 4JJ

Registered Number

05241106 (England and Wales)
MOTTS PHARMACY LIMITED
Balance Sheet as at
28 February 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets397,98051,200
97,98051,200
Current assets
Stocks425,40023,925
Debtors5163,892157,573
Cash at bank and on hand176,571180,698
365,863362,196
Creditors amounts falling due within one year6(270,211)(255,749)
Net current assets (liabilities)95,652106,447
Total assets less current liabilities193,632157,647
Creditors amounts falling due after one year7(34,500)(25,907)
Net assets159,132131,740
Capital and reserves
Called up share capital100100
Profit and loss account159,032131,640
Shareholders' funds159,132131,740
The financial statements were approved and authorised for issue by the Board of Directors on 17 November 2025, and are signed on its behalf by:
KULAR, Gurpreet
Director
Registered Company No. 05241106
MOTTS PHARMACY LIMITED
Notes to the Financial Statements
for the year ended 28 February 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Fixtures and fittings15
Vehicles15
Office Equipment15
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20252024
Average number of employees during the year88
3.Tangible fixed assets

Vehicles

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 March 2413,48977,23427,373118,096
Additions43,9998,0843,75255,835
At 28 February 2557,48885,31831,125173,931
Depreciation and impairment
At 01 March 245,61948,97112,30666,896
Charge for year1,7305,0182,3079,055
At 28 February 257,34953,98914,61375,951
Net book value
At 28 February 2550,13931,32916,51297,980
At 29 February 247,87028,26315,06751,200
4.Stocks

2025

2024

££
Finished goods25,40023,925
Total25,40023,925
5.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables124,454122,868
Other debtors38,16834,364
Prepayments and accrued income1,270341
Total163,892157,573
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables101,651116,457
Bank borrowings and overdrafts821693
Amounts owed to related parties40,50941,345
Taxation and social security14,62710,158
Payments received on account66,86764,822
Finance lease and HP contracts6,049-
Other creditors39,68720,552
Accrued liabilities and deferred income-1,722
Total270,211255,749
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
7.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts16,54925,907
Other creditors17,951-
Total34,50025,907
8.Obligations under finance leases

2025

2024

££
Finance lease and HP contracts23,999-
9.Related party transactions
At the year-end, the company owed £40,509 (2024: £41,345) to G S Kular Ltd, a company in which Mr G. Kular is also a director and a majority shareholder.